2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism
This guideline cites 5 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2019
- Source
- Konstantinides SV, Meyer G, et al. Eur Heart J. 2020;41(4):543–603.doi 10.1093/eurheartj/ehz405
The 2019 ESC guideline makes direct oral anticoagulants the default in acute pulmonary embolism, formalises risk stratification by haemodynamics, right-ventricular function and biomarkers, and confines full-dose systemic fibrinolysis to high-risk disease and to rescue in deteriorating intermediate-risk patients. The register's anticoagulation and reperfusion trials are grouped below.
Anticoagulation: direct oral anticoagulants3
- 2013HOKUSAI-VTECardiology · Thrombosis · Venous thromboembolismIn 8,240 patients with acute venous thromboembolism after initial heparin, once-daily edoxaban was non-inferior for recurrent symptomatic venous thromboembolism and caused less clinically relevant bleeding than warfarin.HR 0.8995% CI 0.70-1.13Read →
- 2013AMPLIFY CoreCardiology · Thrombosis · Venous thromboembolismIn 5,395 patients with acute venous thromboembolism, apixaban was non-inferior to conventional heparin–warfarin therapy for recurrent VTE, with far less major bleeding.2.3% vs 2.7%Read →
- 2012EINSTEIN-PECardiology · Thrombosis · Pulmonary embolismIn 4,832 patients with acute symptomatic pulmonary embolism, single-drug oral rivaroxaban was non-inferior for recurrent venous thromboembolism and halved major bleeding compared with enoxaparin followed by a vitamin K antagonist.HR 1.1295% CI 0.75-1.68Read →
Reperfusion: systemic & catheter-directed2
- 2014PEITHO CoreCardiology · Thrombosis · Pulmonary embolismIn 1,006 patients with intermediate-risk pulmonary embolism, tenecteplase reduced haemodynamic decompensation but increased major and intracranial bleeding compared with heparin alone.OR 0.44Read →
- 2014ULTIMACardiology · Thrombosis · Pulmonary embolismIn 59 patients with intermediate-risk pulmonary embolism and right-ventricular dilatation, ultrasound-assisted catheter-directed thrombolysis reversed the right-ventricular-to-left-ventricular diameter ratio at 24 hours more than unfractionated heparin alone.Read →
Published since the guideline1
- 2020CARAVAGGIOCardiology · Thrombosis · Venous thromboembolismIn 1,170 patients with cancer-associated venous thromboembolism, apixaban was non-inferior to dalteparin for recurrent VTE, without excess major bleeding.HR 0.63Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2017EINSTEIN-CHOICE
Reduced-dose rivaroxaban versus aspirin for extended VTE prevention.
- 2018Hokusai VTE Cancer
Edoxaban versus dalteparin in cancer-associated thrombosis.
- 2018SELECT-D
Rivaroxaban versus dalteparin in cancer-associated thrombosis.
- 2006PIOPED II
CT pulmonary angiography accuracy — the basis of the diagnostic algorithm.
- 2022PEITHO-3 / HI-PEITHO
Reduced-dose and catheter-directed fibrinolysis in intermediate-high-risk PE — the open questions.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.